Novel Small Molecule Antiviral Agents for Treatment of SARS-CoV-2 causing COVID 19 coronavirus disease: Target Identification and Structural Optimization [Funder: MI4]
- Funded by Other Funders (Canada)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
Other Funders (Canada)Principal Investigator
Cosa, GonzaloResearch Location
CanadaLead Research Institution
McGill UniversityResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Pre-clinical studiesSpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
Creating new drugs to treat COVID-19 could save lives. Researchers at the University of Alberta have discovered a chemical compound that prevents RSV, a respiratory virus, from being infectious. McGill chemist Dr. Gonzalo Cosa is partnering with the University of Alberta to investigate whether the compound can be adapted to stop the SARS-CoV-2 virus from being infectious, slowing the spread of the disease. If successful, this new compound could be developed into a drug that effectively treats COVID-19.